Prosecution Insights
Prosecution Insights
7 pending office actions • 3 clients • 7 examiners • 7 art units • 0 of 7 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (14%) |
| §112 only | 2 (29%) |
| Double-patenting + other | 1 (14%) |
| Multi-statute (no §101) | 3 (43%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHAN, KO HUNG | 1 | 66.4% | +15.3% |
| POON, ROBERT | 1 | 42.0% | +26.9% |
| KIM, YOUNG J | 1 | 64.8% | +18.0% |
| YU, MISOOK | 1 | 39.1% | +17.2% |
| HOLTZMAN, KATHERINE ANN | 1 | 67.6% | +55.9% |
| DUFFY, BRADLEY | 1 | 54.6% | +45.4% |
| HOWARD, ZACHARY C | 1 | 63.8% | +38.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18255049 | CD19-TARGETING HUMANIZED ANTIBODY AND USE THEREOF | DUFFY, BRADLEY | 67d overdue |
| 19054939 | Adjustable Furniture Leg Assembly | CHAN, KO HUNG | — |
| 18518873 | STORAGE BOX AND PACKAGING STRUCTURE THEREOF | POON, ROBERT | — |
| 18549084 | MicroRNAs AS BIOMAKERS FOR THE IN VITRO DIAGNOSIS OF GLIOMA | KIM, YOUNG J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18255049 | CD19-TARGETING HUMANIZED ANTIBODY AND USE THEREOF | DUFFY, BRADLEY | 67d overdue |
| 18034167 | BCMA-TARGETING SINGLE-DOMAIN ANTIBODY AND USE THEREOF | HOWARD, ZACHARY C | 30d overdue |
| 18260905 | ROR1-TARGETING ANTIBODY AND USE THEREOF | HOLTZMAN, KATHERINE ANN | 23d overdue |
| 18263439 | NOVEL CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | YU, MISOOK | 85d |
| 19054939 | Adjustable Furniture Leg Assembly | CHAN, KO HUNG | — |
| 18518873 | STORAGE BOX AND PACKAGING STRUCTURE THEREOF | POON, ROBERT | — |
| 18549084 | MicroRNAs AS BIOMAKERS FOR THE IN VITRO DIAGNOSIS OF GLIOMA | KIM, YOUNG J | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Bioheng Therapeutics | 4 |
| Yixiang Blow Molding Furniture Co., Ltd. | 2 |
| ISTITUTI FISIOTERAPICI OSPITALIERI | 1 |
| Art Unit | Apps |
|---|---|
| 3632 | 1 |
| 3735 | 1 |
| 1681 | 1 |
| 1641 | 1 |
| 1646 | 1 |
| 1643 | 1 |
| 1674 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19054939 | Adjustable Furniture Leg Assembly | Yixiang Blow Molding Furniture Co., Ltd. | CHAN, KO HUNG | 3632 | §103§112 | Non-Final OA | — | Pending | Feb 17, 2025 |
| 18518873 | STORAGE BOX AND PACKAGING STRUCTURE THEREOF | Yixiang Blow Molding Furniture Co., Ltd. | POON, ROBERT | 3735 | §102§103§112 | Non-Final OA | — | Pending | Nov 24, 2023 |
| 18549084 | MicroRNAs AS BIOMAKERS FOR THE IN VITRO DIAGNOSIS OF GLIOMA | Istituti Fisioterapici Ospitalieri | KIM, YOUNG J | 1681 | §101§112 | Final Rejection | — | Pending | Sep 05, 2023 |
| 18263439 | NOVEL CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | BIOHENG THERAPEUTICS LIMITED | YU, MISOOK | 1641 | §102§103§112DP | Non-Final OA | 85d | Pending | Jul 28, 2023 |
| 18260905 | ROR1-TARGETING ANTIBODY AND USE THEREOF | BIOHENG THERAPEUTICS LIMITED | HOLTZMAN, KATHERINE ANN | 1646 | §112 | Non-Final OA | 23d overdue | Pending | Jul 10, 2023 |
| 18255049 | CD19-TARGETING HUMANIZED ANTIBODY AND USE THEREOF | BIOHENG THERAPEUTICS LIMITED | DUFFY, BRADLEY | 1643 | §102§103§112 | Non-Final OA | 67d overdue | Pending | May 30, 2023 |
| 18034167 | BCMA-TARGETING SINGLE-DOMAIN ANTIBODY AND USE THEREOF | BIOHENG THERAPEUTICS LIMITED | HOWARD, ZACHARY C | 1674 | §112 | Non-Final OA | 30d overdue | Pending | Apr 27, 2023 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial